SEC Form 4 · accession 0001213900-18-017635
RELMADA THERAPEUTICS, INC. · RLMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maged Shenouda
Director
Period of report
Dec 20, 2018
Accepted (ET)
Dec 20, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001553643
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $1.15 | Dec 20, 2018 | A | 450,000 | A | — | Dec 20, 2028 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.